Natick-based Boston Scientific Corp. announced the start of a new clinical trial involving 500 patients in 15 sites in China.
The randomized trial will test the effectiveness of one of the company’s Promus Element branded coronary stents.
Boston Scientific is seeking approval for the Promus Element stent from the state Food and Drug Administration of the People’s Republic of China.
The first patient in the trial was enrolled this week at Shenyang Northern Hospital.
